The use of biosimilar treatments is increasing, according to surveys conducted in 2018 and 2020 of rheumatologists from eight countries. In the two-year period, Japan had the largest increase in biosimilar prescriptions, with only 6% of surveyed rheumatologists reporting they prefer prescribing originator biologic agents.
![](https://www.the-rheumatologist.org/wp-content/uploads/2017/05/Pharma_Generic_500x270-150x150.jpg)